EMEA-002869-PIP01-21 - paediatric investigation plan

Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1
PIPHuman

Key facts

Active Substance
Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1
Therapeutic area
Vaccines
Decision number
P/0144/2022
PIP number
EMEA-002869-PIP01-21
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of pandemic influenza
Route(s) of administration
Intramuscular use
Contact for public enquiries

Seqirus Netherlands B.V.

E-mail: seqirus.clinicaltrials@seqirus.com
Tel: +1 9088587365

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page